| ROCHE GS | 277.20 / +0.05% |
| Date/Time | 02/22 / 17:31 |
| Chg. / Chg.(%) | 0.15 / +0.05% |
| Bid | 276.20 / 25 |
| Ask | 278.00 / 930 |
| Open | 277.60 |
| Previous Close | 277.05 |
| High | 278.20 |
| Low | 274.50 |
| Volume [CHF] | 301,434,616.85 |
| Volume [Units] | 1,498,831 |
| Price fixings | 10584 |
| ISIN | CH0012032048 |
| Security | ROG |
| Exchange | SIX Swiss Exchange |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| Lang & Schwa.. | 244.324 |  |
|
| SIX Swiss Ex.. | 277.20 | |
1,498,831 |
| London Inter.. | 276.70 | |
161,172 |
| Turquoise | 277.55 |  |
110,050 |
| Cboe Europe .. | 276.75 | |
85,996 |
| Nasdaq Other.. | 276.3400 | |
13,025 |
| Xetra | 243.50 | |
8,558 |
| Frankfurt | 244.050 | |
4,886 |
| TradeGate | 243.800 | |
2,219 |
| Stuttgart | 244.650 | |
327 |
| Borsa Italia.. | 243.10 | |
98 |
| gettex | 244.400 | |
50 |
| Berlin | 244.65 | |
0 |
| Düsseldorf | 244.60 | |
0 |
| München | 244.10 | |
0 |
| Hamburg | 244.20 | |
0 |
| Mexico | 5,345.17 | 361 | |
| Mexico | 4,744.44 | 32 | |
| Borsa Italia.. | 243.10 | ||
| EUREX | Options | ||
News
- FDA grants Priority Review to Roche's personalised medicine entrectinib
02/19/2019 / 07:03 - GlobeNewswire - FDA grants Priority Review to Roche's polatuzumab vedotin in previously treated aggressive lymphoma
02/19/2019 / 07:00 - GlobeNewswire - Global Genetic Testing Market Outlook 2017-2026 - Drivers, Constraints, Opportunities, Threats, Challenges, & Investment Opportunities
02/07/2019 / 19:26 - GlobeNewswire - Roche joins the World Federation of Hemophilia Humanitarian Aid Program
02/06/2019 / 07:00 - GlobeNewswire - Roche submits supplemental biologics license application to US FDA for Kadcyla for adjuvant treatment of people with HER2-positive early breast cancer with residual disease after neoadjuvant treatment
02/05/2019 / 07:00 - GlobeNewswire
Real-time